• In November 2022, Biocare Medical LLC announced the acquisition of Empire Genomics, a company that produces fluorescence in situ hybridization (FISH) probes designed and optimized for specific genes, diseases, or regions across the entire mouse and human genomes.

• In March 2023, Oxford Gene Technology (Sysmex Corporation) announced that eight of its CytoCell FISH probes had been certified for clinical use in line with Europe's In Vitro Diagnostics Regulation (IVDR).

• In April 2023, Agilent Technologies Inc. expanded its portfolio of SureFISH probes. This move was aimed at creating the largest offering of oligonucleotide-based fluorescent in situ hybridization (FISH) assays on the market.

In this report, the Global Fluoroscent In Situ Hybridization (FISH) Probes Market has been segmented by RNA Type, Technology, Application, End Use and Geography.

Global Fluoroscent In Situ Hybridization (FISH) Probes Market, Segmentation by RNA Type

The Global Fluoroscent In Situ Hybridization (FISH) Probes Market has been segmented by RNA Type into mRNA, miRNA and Others.

The mRNA segment dominates the Global Fluorescent In Situ Hybridization (FISH) Probes Market, accounting for approximately 45% of the market share. This dominance is largely attributed to its widespread application in identifying gene expression patterns, particularly in cancer diagnostics and genetic disorders. Increasing adoption in personalized medicine and its compatibility with automated platforms further enhance its growth trajectory.

The miRNA segment holds a notable share of around 30% in the FISH Probes Market. Its importance lies in its ability to regulate gene expression, making it essential in oncology and neurodegenerative disease research. With rising investment in biomarker discovery and non-coding RNA research, the demand for miRNA-based FISH probes continues to grow steadily.

Global Fluoroscent In Situ Hybridization (FISH) Probes Market, Segmentation by Technology

The Global Fluoroscent In Situ Hybridization (FISH) Probes Market has been segmented by Technology into FISH, CISH and DISH.

The fish segment dominates the technology landscape, accounting for around 60% of the total market. Known for its high sensitivity and specificity, fluorescent in situ hybridization is widely used in cancer diagnostics, genetic research, and prenatal testing. Its ability to detect chromosomal abnormalities at the molecular level underpins its extensive clinical adoption.

The cish segment holds a market share of approximately 25%. Chromogenic in situ hybridization offers advantages like permanent staining and compatibility with standard bright-field microscopes, making it a practical choice in routine pathology labs. Its growing use in formalin-fixed, paraffin-embedded (FFPE) samples contributes to its increasing relevance.

The dish segment captures close to 15% of the market and is gaining attention for its application in dual-probe analysis. Dual in situ hybridization allows simultaneous detection of multiple gene targets, enhancing the depth of molecular diagnostics. As demand for multiplex testing rises, this technology is expected to witness progressive growth.

Global Fluoroscent In Situ Hybridization (FISH) Probes Market, Segmentation by Application

The Global Fluoroscent In Situ Hybridization (FISH) Probes Market has been segmented by Application into Cancer diagnostics, Genetic diseases and Others.

The cancer diagnostics segment represents the largest share of the FISH Probes Market, accounting for approximately 50%. This is driven by the high prevalence of cancer worldwide and the crucial role of FISH in detecting chromosomal abnormalities associated with various cancers. Its accuracy and ability to provide rapid, visual results make it indispensable in oncology diagnostics.

The genetic diseases segment holds a market share of about 35%. FISH probes are extensively used in diagnosing hereditary disorders and chromosomal syndromes such as Down syndrome and Klinefelter syndrome. Increasing awareness and accessibility to genetic testing are key factors fueling this segment’s growth.

The ‘Others’ segment, comprising infectious diseases and neurological conditions, makes up nearly 15% of the market. Applications in emerging areas like neurogenetics and microbial diagnostics are gradually expanding the use of FISH probes beyond traditional boundaries, paving the way for broader clinical and research adoption.

Global Fluoroscent In Situ Hybridization (FISH) Probes Market, Segmentation by End Use

The Global Fluoroscent In Situ Hybridization (FISH) Probes Market has been segmented by End Use into Research, Clinical and Companion diagnostics.

The research segment leads the market with a share of approximately 40%. FISH probes are extensively used in molecular biology research to study gene mapping, chromosomal rearrangements, and gene expression patterns. The segment benefits from rising investments in genomics and biotechnology across academic and industrial research institutions.

The clinical segment accounts for nearly 35% of the market. This growth is driven by the increasing adoption of FISH in clinical diagnostics for conditions like cancer and genetic syndromes. Its high accuracy in identifying chromosomal abnormalities enhances its utility in routine clinical pathology.

The companion diagnostics segment holds around 25% market share. It is gaining momentum due to the critical role FISH plays in personalized medicine by identifying patients who are likely to benefit from specific targeted therapies. Regulatory support and pharmaceutical collaborations are accelerating its clinical integration.

Global Fluoroscent In Situ Hybridization (FISH) Probes Market, Segmentation by Geography

In this report, the Global Fluoroscent In Situ Hybridization (FISH) Probes Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Fluoroscent In Situ Hybridization (FISH) Probes Market Share (%), by Geographical Region, 2024

North America leads the FISH Probes Market with a dominant share of around 40%. This leadership is fueled by advanced healthcare infrastructure, strong presence of key market players, and extensive adoption of genetic testing technologies in both research and clinical settings.

Europe holds approximately 25% of the market, driven by its robust healthcare systems and rising prevalence of genetic disorders. Government support for biotechnology research and increasing implementation of personalized medicine initiatives further boost regional demand.

The Asia Pacific region accounts for nearly 20% of the market and is expected to grow rapidly due to expanding healthcare access, a large patient pool, and increasing investments in medical diagnostics. Countries like China and India are emerging as key contributors.

This region represents about 8% of the global market. Growth is supported by gradual improvements in healthcare infrastructure and the introduction of advanced diagnostic technologies in select urban centers, though adoption remains uneven.

Latin America contributes roughly 7% to the global market. Increasing awareness of genetic diseases, government initiatives in public health, and collaboration with global diagnostic companies are driving moderate but steady growth.

This report provides an in depth analysis of various factors that impact the dynamics of Global Fluoroscent In Situ Hybridization (FISH) Probes Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunities Analysis

Drivers

• Advancements in molecular diagnostics
• Increasing prevalence of genetic disorders
• Growing demand for personalized medicine

• Technological innovations in FISH probes - Ongoing advancements in FISH probe technology are significantly accelerating the growth of the Global Fluorescent In Situ Hybridization (FISH) Probes Market. Enhanced fluorophore chemistry, improved probe specificity, and advanced multiplexing capabilities have substantially increased the efficiency and precision of FISH-based diagnostics. These technological improvements are especially crucial for accurately identifying genetic disorders, chromosomal abnormalities, and oncogenic alterations across a broad range of applications.

  One notable innovation is the use of multiplex FISH probes that allow for the detection of multiple gene targets within a single assay. This evolution reduces sample volume, speeds up turnaround times, and supports high-throughput workflows features that are increasingly essential in clinical diagnostics and oncology research. The ability to analyze complex genetic signatures in a single step is transforming how medical professionals approach personalized treatment strategies.

  Integration with automated systems and digital imaging software is further improving the operational efficiency of FISH workflows. These technologies support faster result interpretation, reduce human error, and enhance reproducibility in high-volume laboratories. At the same time, innovations in fluorophore brightness and photostability are delivering clearer and more durable imaging outcomes, improving diagnostic reliability.

  As the demand for accurate, scalable, and adaptable molecular diagnostics continues to rise, technological innovation in FISH probes is expanding their use in clinical laboratories, research centers, and pharmaceutical development. These innovations are laying the foundation for broader adoption and long-term growth across multiple healthcare domains.

Restraints

• High cost of FISH probes
• Regulatory challenges in market approval
• Limited reimbursement policies

• Lack of skilled professionals - One of the primary limitations impacting the adoption of FISH probe technologies is the shortage of trained professionals. FISH procedures require specialized skills in probe handling, hybridization, and fluorescence microscopy, along with accurate interpretation of complex imaging data. In many laboratories, particularly in emerging economies, the absence of adequately trained cytogeneticists and technicians undermines diagnostic efficiency and consistency.

  This expertise gap can lead to inconsistent results, misinterpretation, and diagnostic errors, even in facilities equipped with advanced tools. Without proper knowledge of probe behavior and analytical protocols, laboratories risk compromised diagnostic accuracy, which can affect patient outcomes and reduce trust in molecular diagnostic methods.

  The need to master advanced imaging software and digital analysis tools adds another layer of complexity for staff unfamiliar with such platforms. Many institutions lack the infrastructure or funding to offer structured training programs, leading to operational dependency on third-party diagnostic centers or reference labs, which increases turnaround time and testing costs.

  To address this constraint, significant investments are required in education, certification programs, and hands-on training modules. Until this workforce shortage is resolved, the lack of skilled personnel will continue to be a barrier to widespread FISH adoption, particularly in high-demand clinical and research environments.

Opportunities

• Expansion in emerging markets
• Rising focus on cancer diagnostics
• Development of multiplex FISH assays

• Collaborations for R&D activities - Expanding collaborations in research and development are creating valuable opportunities in the Global Fluorescent In Situ Hybridization (FISH) Probes Market. Partnerships among biotech companies, academic institutions, and diagnostic manufacturers are accelerating the pace of innovation in FISH probe design and implementation. These alliances facilitate the sharing of technical expertise, reduce development timelines, and help bring advanced solutions to market more efficiently.

  Collaborative R&D efforts are focusing on creating customized probes for rare genetic conditions, disease-specific markers, and high-throughput testing environments. Such targeted innovations are increasing the clinical relevance of FISH, particularly in precision medicine applications where individualized diagnostics are becoming standard. These efforts also support faster hybridization techniques, improved signal clarity, and automation-ready probe kits.

  Support from government-funded initiatives, innovation grants, and public-private partnerships is further reinforcing collaborative momentum. These programs not only fuel development but also ensure that resulting technologies meet regulatory and clinical standards. By bridging research with commercialization, collaborations help convert scientific insights into viable diagnostic products.

  As the global demand for advanced and scalable diagnostic tools continues to rise, R&D partnerships are helping to position FISH probes as indispensable components of the molecular diagnostics toolkit. These collaborative strategies are unlocking new applications, enhancing product pipelines, and fostering sustainable growth across the FISH probes landscape.

Key players in Global Fluoroscent In Situ Hybridization (FISH) Probes Market include:

• Mirus Bio LLC
• Life Science Technologies
• PerkinElmer Inc
• BioDot Inc
• Horizon Diagnostics
• Sigma-Aldrich Corporation
• Agilent Technologies
• Abnova Corporation
• Biosearch Technologies Inc
• F. Hoffman-La Roche AG - Life Science

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis